Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multivalent HIV-1 peptide immunogen
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptides, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A synthetic peptide-based prophylactic vaccine designed to elicit broad immune responses against diverse strains of human immunodeficiency virus type 1 (HIV-1). The formulation consists of branched synthetic peptides derived from the principal neutralizing domain (PND) of the gp120 envelope protein, representing sequences from multiple viral strains worldwide. This multivalent approach aims to address global sequence diversity and induce both humoral and cellular immunity, including neutralizing antibodies and T cell responses. The vaccine is intended for prevention of HIV infection in uninfected individuals. It was developed by the National Institute of Allergy & Infectious Diseases with United Biomedical as a collaborator[3][5].
- Other names
- multivalent HIV-1 peptide vaccineUBI Multivalent HIV-1 Peptide Immunogen
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on multivalent HIV-1 peptide immunogen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multivalent HIV-1 peptide immunogen.